Amneal Pharmaceuticals (AMRX) Retained Earnings (2017 - 2025)
Amneal Pharmaceuticals (AMRX) has 9 years of Retained Earnings data on record, last reported at -$110.7 million in Q4 2025.
- For Q4 2025, Retained Earnings rose 81.76% year-over-year to -$110.7 million; the TTM value through Dec 2025 reached -$110.7 million, up 81.76%, while the annual FY2025 figure was -$110.7 million, 81.76% up from the prior year.
- Retained Earnings reached -$110.7 million in Q4 2025 per AMRX's latest filing, up from -$570.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $12.5 million in Q3 2022 and bottomed at -$607.1 million in Q4 2024.
- Average Retained Earnings over 5 years is -$194.2 million, with a median of -$54.1 million recorded in 2021.
- Peak YoY movement for Retained Earnings: surged 140.03% in 2022, then plummeted 46322.24% in 2023.
- A 5-year view of Retained Earnings shows it stood at -$24.8 million in 2021, then skyrocketed by 140.03% to $9.9 million in 2022, then tumbled by 5031.84% to -$490.2 million in 2023, then dropped by 23.85% to -$607.1 million in 2024, then soared by 81.76% to -$110.7 million in 2025.
- Per Business Quant database, its latest 3 readings for Retained Earnings were -$110.7 million in Q4 2025, -$570.1 million in Q3 2025, and -$572.4 million in Q2 2025.